FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134870122> ?p ?o ?g. }

• W3134870122 endingPage "375" @default.
• W3134870122 startingPage "375" @default.
• W3134870122 abstract "375 Background: Chemotherapy or radiotherapy are standard treatments for stage II seminoma, though they are associated with significant long-term treatment-related toxicities. Retroperitoneal lymph node dissection (RPLND) is an established treatment for testicular germ cell tumors but little data exists on its efficacy as a front-line treatment in early metastatic (stage II) seminoma. This is a single-arm, multi-institutional (NCT02537548), phase II study of retroperitoneal lymph node dissection (RLND) as first-line treatment for testicular seminoma with isolated retroperitoneal disease. Methods: Twelve sites in the United States and Canada prospectively enrolled patients (16 years of age) with testicular seminoma and isolated retroperitoneal lymphadenopathy between 1-3 cm in size. Patients were excluded if they received prior therapy (except orchiectomy) for testicular cancer. Open, modified-template RPLND was performed by qualified surgeons with a primary endpoint of 2-year recurrence-free survival. Data on complication rates (short and long-term), pathologic up/downstaging, recurrence patterns, adjuvant therapies, and treatment-free survival were assessed. Results: A total of 55 patients were enrolled and underwent RPLND. Fourteen patients had initial stage I disease who developed isolated retroperitoneal relapse while 41 patients had clinical stage IIA-B at presentation. With a median follow-up of 24 months (8-52 months), there were a total of 10 recurrences. The overall recurrence rate was 18% with a median time to recurrence of 8 months. Of the recurrences, 8 underwent chemotherapy (6 BEP X 3, 1 EP X 4, 1 carbo/etoposide) and 2 underwent additional surgery. The two-year recurrence free survival was 87% and the overall survival was 100%. There were 7 (13%) patients who experienced short-term complications within 1 year of RPLND. Of these, 5 (9%) were classified as Clavien Dindo I-II and 2 (3.6%) were classified as Clavien Dindo III. No patients have reported long-term complications. Conclusions: This trial establishes RPLND as a therapeutic option as a first-line treatment in early metastatic seminoma. The surgery offers cancer control rates similar to those seen in non-seminomatous germ cell tumors. Clinical trial information: NCT02537548." @default.
• W3134870122 created "2021-03-15" @default.
• W3134870122 creator A5009058837 @default.
• W3134870122 creator A5014984711 @default.
• W3134870122 creator A5018095179 @default.
• W3134870122 creator A5018329690 @default.
• W3134870122 creator A5019615102 @default.
• W3134870122 creator A5029009031 @default.
• W3134870122 creator A5039864912 @default.
• W3134870122 creator A5047242967 @default.
• W3134870122 creator A5047940829 @default.
• W3134870122 creator A5048544130 @default.
• W3134870122 creator A5050196540 @default.
• W3134870122 creator A5057040034 @default.
• W3134870122 creator A5067264659 @default.
• W3134870122 creator A5067558680 @default.
• W3134870122 creator A5073077227 @default.
• W3134870122 creator A5075516105 @default.
• W3134870122 creator A5077644150 @default.
• W3134870122 creator A5086407520 @default.
• W3134870122 creator A5087150696 @default.
• W3134870122 date "2021-02-20" @default.
• W3134870122 modified "2023-10-14" @default.
• W3134870122 title "SEMS trial: Result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma." @default.
• W3134870122 doi "https://doi.org/10.1200/jco.2021.39.6_suppl.375" @default.
• W3134870122 hasPublicationYear "2021" @default.
• W3134870122 type Work @default.
• W3134870122 sameAs 3134870122 @default.
• W3134870122 citedByCount "25" @default.
• W3134870122 countsByYear W31348701222021 @default.
• W3134870122 countsByYear W31348701222022 @default.
• W3134870122 countsByYear W31348701222023 @default.
• W3134870122 crossrefType "journal-article" @default.
• W3134870122 hasAuthorship W3134870122A5009058837 @default.
• W3134870122 hasAuthorship W3134870122A5014984711 @default.
• W3134870122 hasAuthorship W3134870122A5018095179 @default.
• W3134870122 hasAuthorship W3134870122A5018329690 @default.
• W3134870122 hasAuthorship W3134870122A5019615102 @default.
• W3134870122 hasAuthorship W3134870122A5029009031 @default.
• W3134870122 hasAuthorship W3134870122A5039864912 @default.
• W3134870122 hasAuthorship W3134870122A5047242967 @default.
• W3134870122 hasAuthorship W3134870122A5047940829 @default.
• W3134870122 hasAuthorship W3134870122A5048544130 @default.
• W3134870122 hasAuthorship W3134870122A5050196540 @default.
• W3134870122 hasAuthorship W3134870122A5057040034 @default.
• W3134870122 hasAuthorship W3134870122A5067264659 @default.
• W3134870122 hasAuthorship W3134870122A5067558680 @default.
• W3134870122 hasAuthorship W3134870122A5073077227 @default.
• W3134870122 hasAuthorship W3134870122A5075516105 @default.
• W3134870122 hasAuthorship W3134870122A5077644150 @default.
• W3134870122 hasAuthorship W3134870122A5086407520 @default.
• W3134870122 hasAuthorship W3134870122A5087150696 @default.
• W3134870122 hasConcept C126322002 @default.
• W3134870122 hasConcept C141071460 @default.
• W3134870122 hasConcept C146357865 @default.
• W3134870122 hasConcept C151730666 @default.
• W3134870122 hasConcept C2776212926 @default.
• W3134870122 hasConcept C2776694085 @default.
• W3134870122 hasConcept C2776938808 @default.
• W3134870122 hasConcept C2778074268 @default.
• W3134870122 hasConcept C2778119113 @default.
• W3134870122 hasConcept C2778623998 @default.
• W3134870122 hasConcept C2779511695 @default.
• W3134870122 hasConcept C2780824555 @default.
• W3134870122 hasConcept C2780849966 @default.
• W3134870122 hasConcept C509974204 @default.
• W3134870122 hasConcept C71924100 @default.
• W3134870122 hasConcept C86803240 @default.
• W3134870122 hasConceptScore W3134870122C126322002 @default.
• W3134870122 hasConceptScore W3134870122C141071460 @default.
• W3134870122 hasConceptScore W3134870122C146357865 @default.
• W3134870122 hasConceptScore W3134870122C151730666 @default.
• W3134870122 hasConceptScore W3134870122C2776212926 @default.
• W3134870122 hasConceptScore W3134870122C2776694085 @default.
• W3134870122 hasConceptScore W3134870122C2776938808 @default.
• W3134870122 hasConceptScore W3134870122C2778074268 @default.
• W3134870122 hasConceptScore W3134870122C2778119113 @default.
• W3134870122 hasConceptScore W3134870122C2778623998 @default.
• W3134870122 hasConceptScore W3134870122C2779511695 @default.
• W3134870122 hasConceptScore W3134870122C2780824555 @default.
• W3134870122 hasConceptScore W3134870122C2780849966 @default.
• W3134870122 hasConceptScore W3134870122C509974204 @default.
• W3134870122 hasConceptScore W3134870122C71924100 @default.
• W3134870122 hasConceptScore W3134870122C86803240 @default.
• W3134870122 hasIssue "6_suppl" @default.
• W3134870122 hasLocation W31348701221 @default.
• W3134870122 hasOpenAccess W3134870122 @default.
• W3134870122 hasPrimaryLocation W31348701221 @default.
• W3134870122 hasRelatedWork W174998155 @default.
• W3134870122 hasRelatedWork W1991418137 @default.
• W3134870122 hasRelatedWork W2025619963 @default.
• W3134870122 hasRelatedWork W2031233758 @default.
• W3134870122 hasRelatedWork W2074617918 @default.
• W3134870122 hasRelatedWork W2212630809 @default.
• W3134870122 hasRelatedWork W2804633148 @default.
• W3134870122 hasRelatedWork W2890181724 @default.
• W3134870122 hasRelatedWork W3134870122 @default.
• W3134870122 hasRelatedWork W4243770036 @default.

• next